- Home
- EPM vs INO Comparison
EPM vs INO Comparison
Compare EPM & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPM | INO |
|---|---|---|
| Founded | 2003 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.7M | 118.9M |
| IPO Year | 1996 | 1999 |
Fundamental Metrics
Financial Performance| Metric | EPM | INO |
|---|---|---|
| Price | $3.61 | $1.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.83 | ★ $6.75 |
| AVG Volume (30 Days) | 537.4K | ★ 3.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.08% | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,229,621.00 | $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $3.19 | $0.56 |
| 52 Week High | $5.10 | $2.72 |
Technical Indicators
Market Signals| Indicator | EPM | INO |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 55.40 |
| Support Level | $3.48 | $1.22 |
| Resistance Level | $3.79 | $1.79 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 17.11 | 50.51 |
Price Performance
Historical ComparisonAbout EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.